UNIVERSITY OF BIRMINGHAM

Symptoms of COPD in the absence of airflow obstruction are more indicative of pre-COPD than overdiagnosis

Spittle, Daniella A.; Thomas, Maximillian; Stevens, Caitlin; Gazwani, Abdulrhman; Fenton, Sally; De Soyza, Joshua; Turner, Alice M.

[Link to publication on Research at Birmingham portal](#)

Symptoms of COPD in the absence of airflow obstruction are more indicative of pre-COPD than overdiagnosis

Daniella A. Spittle, Maximillian Thomas, Caitlin Stevens, Abdulrhman Gazwani, Sally Fenton, Joshua De Soyza, Alice M. Turner

Symptoms of COPD in the absence of airflow obstruction are more indicative of pre-COPD than overdiagnosis

Daniella A Spittle[1], Maximillian Thomas[2], Caitlin Stevens[2], Abdulrhman Gazwani[1], Sally Fenton[3,4], Joshua De Soyza[2,5] & Alice M Turner[2,5]

[1] Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom
[2] University Hospitals Birmingham Foundation Trust, Birmingham, United Kingdom
[3] School of Sport, Exercise and Rehabilitation Sciences, University of Birmingham, Birmingham, United Kingdom
[4] NIHR Birmingham Biomedical Research Centre, Birmingham, United Kingdom
[5] Institute of Applied Health Research, University of Birmingham, Birmingham, United Kingdom

Abstract

Dysfunction of the small airways is a precursor of COPD but is not detectable on standard spirometric testing until significant destruction has occurred. A proportion of COPD patients have an FEV1/FVC less than 0.7 which is greater than the lower limit of normal (LLN), when adjusted for their age and sex. It is not understood whether this group of patients, known as "discordant COPD" are representative of "early COPD" or overdiagnosis. We sought to characterise discordant COPD (disCOPD), using radiology, lung function, serum biomarkers, activity monitoring and quality of life scores, comparing with COPD patients with an FEV1/FVC<0.7 and <LLN and healthy, age-matched controls. Six out of 8 serum biomarkers were significantly different in the disCOPD group versus healthy controls, as were the scores of all 4 QoL questionnaires. Activity monitoring revealed similar levels of sedentary time between the disCOPD group and concordant COPD (conCOPD). CT analysis showed less involvement of small airway dysfunction and emphysema in the disCOPD group versus

conCOPD. Collectively, our findings support the hypothesis that disCOPD is a clinically relevant phenomenon that represents a pre-COPD state. Identification of such patients is important for early intervention and management before progression to fully established COPD.

Introduction

COPD is a progressive respiratory condition that affects nearly 2% of the UK adult population, and causes significant morbidity and mortality (1). It typically affects older adults, frequently with a history of tobacco smoking, commonly causing dyspnoea, wheeze, a cough that may be productive, and frequent exacerbations. Small airway dysfunction (SAD) is a precursor and central feature of COPD. The small airways are known as the "silent" zone, as changes such as airway remodelling, mucus plugging and immune cell infiltration occur in the absence of clinical symptoms (2). Changes in standard lung function only become detectable once around 75% of small airways have been destroyed (3). Identifying patients who may have SAD but have not yet progressed to fully established COPD has important implications for intervention and management of these "pre-COPD" patients. The Global Initiative for COPD 2023 report identified these pre-COPD patients as a priority for further research, specifically the identification of patients that later develop COPD and assessment of interventions that may slow or halt this process (4). Whilst computer tomography (CT) guided measurement of lung volumes have been shown to predict progression to COPD, the feasibility and cost-effectiveness of this is questionable (5, 6).

Diagnosis of COPD is typically based on clinical presentation and traditional spirometry showing airflow obstruction. However, spirometry is a poor tool in the early stages of the disease and can result in unreliable measurements (4). Additionally, there is increasing evidence of age-related decline in the FEV1/FVC ratio that is used to diagnose COPD, in the absence of clinically significant respiratory disease (7). As such, there is a proportion of "discordant" COPD patients, whose FEV1/FVC ratio is less than 0.7, but not less than the lower limit of normal (LLN) when adjusted for their age and sex. This may lead to overdiagnosis

of the healthy elderly population. Another group is recognised, referred to as preserved ratio impaired spirometry (PRISm) who have a preserved ratio (>0.7) but impaired spirometry such as reduced FEV1 or FVC. This group represents up to 12% of the population and is independently associated with morbidity and mortality (8). Investigating discordant and PRISm patients through other methods, such as CT scans, other measures of lung function and biomarkers is crucial to help characterise the early stages of the disease and differentiate early COPD changes which require follow up from age-related changes. There is currently data on CT changes in PRISm patients, as well increasing evidence on the use of biomarkers in characterising SAD (9, 10).

We conceived this study to investigate if 'discordant COPD' was more likely to represent disease or over-diagnosis, by conducting more detailed phenotyping of SAD and emphysema, hypothesising that either of these problems could exist prior to the development of spirometrically-defined COPD. By using a mixed methodology of radiology, lung function, biomarkers, and quality of life (QoL) measurements, we aimed to complete a comprehensive assessment of lung pathology and its impact on these patients.

Methods

Study design

We used an observational cohort study design, to assess the degree and nature of SAD in COPD cases and healthy, age-matched controls. The study was ethically approved (IRAS ID: 253739) and all subjects gave informed consent.

Study population

COPD patients and healthy controls were recruited from a multi-site NHS trust in Birmingham, UK. All patients were over the age of 60. Control patients were recruited from previous research databases such as the Healthy Elders cohort (11). The COPD patients were divided into concordant (FEV1/FVC<0.7 and <LLN; conCOPD) and discordant (FEV1/FVC< 0.7 but >LLN, disCOPD). Importantly this is not the same as PRISM, where FEV/FVC is >0.7. The

control patients were confirmed to have no obstruction on their spirometry (FEV1/FVC>0.7). Exclusion criteria included inability to understand or speak English, and presence of clinically significant lung disease other than COPD. COPD patients were excluded if they had an exacerbation within the prior 6 weeks. Data on co-morbid diseases were collected from the medical record.

Lung function

Pulmonary function measurements were made during baseline visit. Spirometry, gas transfer, and static lung volumes (Ultima PFT Series, Medical Graphics, UK) and forced oscillatory technique (Resmon Pro, Intermedical, UK) were measured by a clinical scientist in a respiratory physiology laboratory. Lung clearance index (5%) was obtained using a nitrogen washout technique (Ultima PFT Series, Medical Graphics, UK). Global Lung Function Initiative (GLI) (2012) reference equations were used to determine percentage predicted and LLN. Percent predicted values account for age and sex, thus had potential to offset any eventual differences in these between groups.

Symptoms and quality of life (QoL)

All patients completed 4 health-related QoL questionnaires; the St George's Respiratory Questionnaire (SGRQ) for impact of respiratory disease on health; the SF-36 for a measure of self-reported health status; the Baseline Dyspnoea Index (BDI) for impact of dyspnoea on daily life; and the COPD Assessment Test (CAT) for the impact of COPD-symptoms on daily life.

Physical Activity Monitoring

All subjects were given a GT3X Actigraph accelerometer (Pensacola, Florida, USA) to wear for 1 week, to provide information about their levels of physical activity. The accelerometer was worn on the right hip, and participants were asked to remove the device for sleeping and water-based activities. The GT3X was set to record accelerations in 10-second epochs, which

were subsequently converted into activity counts, and interpreted to determine the frequency, intensity and duration of physical activity.

Data collected by the GT3X was analysed using the Actilife Software (Version 6). For inclusion in analysis, all participants were required to have for the GT3X for ≥10 hours, on ≥4 days. Non-wear time was defined as 60 minutes of zero counts, with a spike tolerance of 2 minutes (12). Time spent sedentary, and in light, moderate and vigorous intensity physical activity, were determined using accelerometer cut-points used in previous research with adults (i.e. sedentary time = ≥100 counts/min, light-intensity physical activity = 101 – 2019 counts/min, moderate-to-vigorous intensity physical activity = ≥2020 counts/min) (13).

Biomarkers

Blood samples were drawn and centrifuged at 1000 x g for 10 minutes to obtain serum. Serum aliquots were stored at -80°C until further required. Blood biomarkers identified in our previous literature review (CC-16, RAGE, SPD, MMP-8, MMP-9, MMP-12, PAI-1 and CCL-18) were measured using commercially available enzyme-linked immunosorbent assay (ELISA) kits or a Luminex®-based platform (10) (details in supplementary material).

CT scans

COPD patients had CT scans performed to assess for the presence of emphysema and SAD. The study protocol required inspiratory and expiratory scanning. Non-contrast CT imaging was performed in the caudo-cranial direction while patients were supine, fully inhaled and exhaled, with image acquisition using the CT system (SOMATOM go, Siemens Healthineers, Germany). All scans were reviewed by a radiologist for clinical abnormalities prior to quantitative analysis. Parametric response mapping was performed, according to classification criteria described by Vasilescu et al. (14). For full details of CT protocol, see supplementary material.

Statistical analysis

Statistical analysis was conducted using R and significance assumed at p <0.05. Descriptive statistics were calculated for patient characteristics, including biomarkers, lung function, CT parameters, symptoms and the amount of time spent doing different activity levels for each of the three groups. Comparison of variables between health, discordant and concordant COPD were performed using ANOVA, Kruskal-Wallis or multiple analysis of variance (MANOVA) tests. Categorical data were analysed via Fisher's exact test. Data are shown as mean (SD) for normally distributed data and median [IQR] for non-normally distributed data.

Results

Sixty-four patients were recruited from December 2019 to October 2022. Significant pauses to recruitment and study assessments occurred during the Covid-19 pandemic. Patient characteristics are shown in table 1. Most clinically diagnosed COPD patients were taking treatment, namely SABA alone (17.1%), LAMA or LABA (31.4%), or LAMA/LABA/ICS (28.6%), with >95% of conCOPD patients taking regular treatment. Amongst disCOPD patients, regular treatment was far less universal. Fostair (steroid and LABA) and Trimbow® (steroid and LABA/LAMA), inhalers likely to penetrate the small airways, were used in 21% disCOPD and 29% conCOPD. The proportion of patients with clinically significant comorbidities that may affect study outcome measures (e.g. cardiac disease, which can impact shortness of breath and orthopaedic issues which can impact physical activity) did not differ between disCOPD and conCOPD (51% and 43% respectively; p=0.407). Pulmonary hypertension was not reported in the medical history for any included subject.

Table 1: Subject characteristics and pulmonary function parameters for healthy controls, discordant COPD (disCOPD) and concordant COPD (conCOPD).

Demographics	Healthy controls	disCOPD	conCOPD	p value
N	29	14	21	
Age	72.0 ± 8.5	75.5 [8.5]	66.0 [6.5]	**0.002**
Gender (M/F)	8/21	9/5	9/12	0.07

Race (%white)	100%	85.7%	90.4%	0.1
Body Mass Index	25.9 ± 7.8	28.4 [9.5]	26.20 [5.75]	0.3
Smoking status (never/ex/current)	15/14/0	0/12/2	0/11/10	**<0.001**
Pack/yrs	0.0 [14.3]	35.0 [66.5]	42.5 [40]	**<0.001**
Pulmonary Function Measurements				
FEV1 (%pred)	105.1 (13.5)	84.6 (8.5)	80.9 (13.9)	**<0.001**
FVC (%pred)	107.0 (14.5)	93.9 (8.5)	108.8 (14.7)	**0.005**
FEV1/FVC (%)	76.4 (4.4)	68.8 (3.0)	57.6 (6.8)	**<0.001**
MMEF25-75 (%pred)	107.0 (31.7)	66.1 (13.5)	41.8 (12.6)	**<0.001**
TLC (%pred)	98.4 (10.6)	97.5 (10.3)	111.4 (13.3)	**0.001**
FRC (%pred)	92.1 (21.5)	94.2 (15.6)	118.5 (27.0)	**0.001**
RV (%pred)	90.8 (20.0)	107.3 (18.4)	116.6 (31.6)	**0.005**
RV/TLC (%)	38.9 (4.5)	43.3 (5.7)	39.1 (5.6)	**0.073**
TLco (%pred)	109.6 (19.3)	93.9 (20.6)	79.9 (14.4)	**<0.001**
Kco (%pred)	103.8 (13.9)	92.5 (19.4)	71.2 (14.0)	**<0.001**
VA (%pred)	97.3 (10.7)	100.9 (6.6)	112.2 (11.1)	**<0.001**
LCI	8.20 [1.68]	9.18 [0.98]	8.11 [1.49]	**0.005**
R5Hz (%pred)	110.2 (30.1)	140.7 (54.9)	135.8 (42.9)	0.08
X5Hz (%pred)	106.3 (41.2)	177.0 (63.2)	179.3 (120.9)	**0.03**
R11Hz (%pred)	113.9 (30.5)	133.1 (52.3)	131.6 (38.6)	0.3
R19Hz (%pred)	103.9 (22.8)	114.8 (39.9)	114.5 (32.7)	0.5
R5-19	0.32 (0.2)	0.78 (0.40)	0.59 (0.74)	**0.04**

Data presented as mean (SD) or median [IQR]. ANOVA and Kruskal-Wallis tests were performed appropriately. FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; MMEF, maximal mid expiratory flow; TLC, total lung capacity; FRC, functional residual capacity; TLco, transfer capacity of the lung; Kco, carbon monoxide transfer coefficient; VA, alveolar volume; LCI, lung clearance index; R#Hz, resistance measured by forced oscillometry technique, X#Hz, reactance measured by forced oscillometry technique.

Lung function

Most patients had mild COPD, as demonstrated by FEV1 >80% predicted; this was our aim in recruitment, to best identify aspects relevant to early diagnosis. ConCOPD patients were younger (p=0.002) with mean TLco and Kco <80%pred (both p<0.001) and elevated TLC and FRC (both p=0.001) implying that emphysema and hyperinflation are confined to this group. Established SAD markers were more aberrant in COPD v health, with lower FEV1/FVC, lower MMEF25-75, raised X5Hz and raised R5-19 on Forced Oscillation Technique (all p≤0.04). Notably, disCOPD exhibited differences in oscillometry from health, and higher LCI (p=0.005).

Symptoms and quality-of-life outcomes

Four questionnaires were completed that captured QoL measurements for both respiratory-based outcomes (CAT, SGRQ and BDI) and general health status (SF36), shown in table 2.

COPD patients reported worse impact on QoL than the control patients in all questionnaires. A sequential trend was observed across all scores, whereby the median value worsened (higher or lower, depending on individual score interpretation) with disCOPD being worse than healthy, and conCOPD being worse than disCOPD. No significance was observed between the dis- and conCOPD groups for any questionnaire.

Table 2: Quality-of-life scores

	Healthy controls	**disCOPD**	**conCOPD**	**p value**
CAT (total score)	5 [2-8]	16.5 [10.5-27]	24 [13-30.8]	<0.0001
SGRQ (subscale scores)				
Symptoms	3.8 [0-33.5]	50.2 [26-71.5]	72.7 [68.3-87.7]	<0.0001
Activity	11.3 [0-29.9]	47.6 [23.1-73]	66.1 [54.5-94.6]	<0.0001
Impact	0 [0-7.1]	18.8 [11.2-49.1]	40.3 [18.2-67.7]	<0.0001
BDI (total score)	11 [9.5-12]	9 [5-9]	5 [3-11]	0.004
SF36 (subscale scores)				

Physical functioning	92.5 [85-100]	42.5 [12.5-85]	35 [15-67.5]	<0.0001
Role limitations due to physical health	100 [100-100]	62.5 [0-100]	25 [0-100]	0.01
Role limitations due to emotional problems	100 [100-100]	50 [0-100]	66.7 [0-100]	0.01
Energy/fatigue	85 [70-90]	62.5 [30-76.3]	40 [30-67.5]	<0.0001
Emotional wellbeing	90 [85-96]	80 [56-94]	56 [40-78]	0.0001
Social functioning	100 [78.1-100]	75 [34.4-100]	50 [25-75]	0.001
Pain	95 [71.9-100]	62.5 [30-85]	60 [27.5-85]	0.04
General health	80 [70-88.8]	42.5 [30-60]	35 [20-55]	<0.0001
*Data presented as Median [IQR]; g***roups were compared using the Kruskal-Wallis test. CAT, COPD Assessment Test; SGRQ, St George's Respiratory Questionnaire; BDI, Baseline Dyspnoea Index and SF36, Short Form Healthy Survey with 36 questions. CAT n=49, SGRQ n=52, SF36 n=51, BDI n=39**				

Physical activity monitoring

Twenty seven of the 64 patients in the study returned activity monitors with successful recordings (n, healthy controls=14, disCOPD=4, conCOPD=9). This is due to a combination of failure to retrieve the devices, loss to follow up and device failure). Due to the low numbers in each group, only descriptive analysis could be undertaken.

On average, participants wore the accelerometer for 13.0 ± 0.89 hours each day. In all three groups, the majority of accelerometer wear time was spent engaged in sedentary time (healthy control=73%, disCOPD=72%, conCOPD=81%), Lower proportions of time spent in moderate-to-vigorous physical activity were seen in COPD overall (healthy control = 5%, disCOPD=3%, conCOPD=2%), but light-intensity physical activity seemed to be maintained by disCOPD patients, compared to healthy controls (healthy control=16%, disCOPD=21%, conCOPD=17%).

Biomarkers

A total of 8 biomarkers were measured in the serum of 55 subjects: 18 healthy controls, 13 with disCOPD and 24 with conCOPD. 6 out of 8 biomarkers displayed significant difference between the three groups. Both PAI-1 and CCL18 were significantly higher in the serum of disCOPD versus healthy controls (p=0.02 and p=0.0006, respectively). PAI-1, CCL18 and MMP-8, -9 and -12 were all significantly higher in the conCOPD compared to the healthy controls (p=0.003, p=0.0009, p=0.0005, p<0.0001 and p=0.01, respectively). CC16 was significantly lower in the conCOPD group versus healthy controls (p=0.006). The only significant difference observed between the COPD groups was for MMP-12, where serum concentration was significantly higher in the conCOPD group versus disCOPD (p=0.02).

CT scans

35 patients with COPD were scheduled to have a CT scan of whom 22 patients had the required inspiratory and expiratory CT scan, 8 patients had a clinical inspiratory CT scan only, 4 patients declined CT scan, 1 patient died before CT scanning could be performed. No patients had interstitial disease or significant pulmonary vascular abnormalities on imaging.

Quantitative CT measures between discordant and concordant COPD groups were compared (figures 1, 2, and 3). A decrease in total pulmonary volume from inspiration to expiration phase in disCOPD group was noted (Figure 1). Both groups showed a similar range of PRM Norm, with the median value lower in the conCOPD group (Figure 2). In addition, we observed a lower proportional PRMEmph and PRMfSAD in disCOPD patients (Figure 3). However, the difference in quantitative lung morphology between disCOPD and conCOPD groups was not statistically significant (total pulmonary volume at the peak of inspiration and expiration, p=0.14; PRMNorm, p=0.24; PRMEmph, p=0.25; PRMfSAD, p=0.19). See also supplementary table 1.

Discussion

These results suggest that disCOPD may be a clinically significant disease, not a form of overdiagnosis. disCOPD patients had symptoms, physical activity, quantitative radiology and

biomarker concentrations more closely resembling conCOPD than health. It emphasises the importance of global assessment of the patient, especially when there is high clinical suspicion of COPD, or a COPD like illness.

Clinical diagnosis of COPD, defined by a diagnostic label having been given to the patient by their primary care provider, did not result in treatment for all disCOPD individuals - prevalence of inhaled treatment was near universal in the case of conCOPD but approaching 50% in the disCOPD group. This may reflect the fact that a COPD diagnosis should be physiologically confirmed, and in the absence of this (in this case FEV1/FVC >LLN) arguably those individuals did not meet current guidelines for a COPD diagnosis and thus management. However, the more detailed clinical data suggested a significant symptom burden from all questionnaires, implying that disCOPD patients may require treatment in the same manner as conCOPD.

There was no evidence of emphysema or hyperinflation on lung function in disCOPD patients, despite the presence of SAD, highlighting the potential for misdiagnosis of early COPD due to silent SAD. Whilst formal statistical analysis of accelerometer data was not possible, descriptive estimates suggested similar levels of sedentary time across all groups, with the conCOPD group demonstrating the highest time spent sedentary. There was evidence of some preserved light-intensity physical activity in the disCOPD group when compared to conCOPD patients; there could be potential to further improve levels of light-intensity physical activity if regular inhaled therapy was more common. This again suggests that the disCOPD group are perhaps a precursor to the conCOPD group, and that their physical activity levels may reduce further as the disease progresses. A randomised, placebo-controlled trial investigated the efficacy of inhaled nitrous oxide (iNO) in improving physical activity in pulmonary fibrosis patients (15). Using actigraphy as a measure of physical activity, the trial showed an increase in moderate to vigorous activity in those receiving iNO versus placebo.

Studies showing the benefit of inhaled bronchodilators, in the absence of airflow obstruction, have not shown clear benefit for physical activity levels, though evidence is limited (16).

Blood biomarkers were also indicative of a pathophysiological burden in disCOPD. A broad range of serum concentrations were observed in the disCOPD cohort, with a distinct population existing above or below the median value (depending on direction of significance). This population may represent an "at-risk" group of patients that may progress to developing conCOPD. We measured eight biomarkers which have evidence of involvement in SAD (10). CC16 is expressed largely by club cells in the small airways and is believed to have a protective role within the airways. In a longitudinal cohort, low serum CC16 was associated with accelerated lung function decline (17). Our results were consistent with this; decreasing levels of serum CC16 from healthy controls to disCOPD, and further in conCOPD, were observed. Similarly, an inverse association with MMPs -8 and -9 with lung function was observed. This trend is widely acknowledged in previous COPD studies and is likely reflective of increasing extracellular matrix degradation (18, 19). More specifically, MMP concentrations have shown a clear association with radiologically-confirmed SAD (20). Serum levels of PAI-1 increased with worsened FEV1; PAI-1 is a serine protease inhibitor, associated with several inflammatory conditions, considered to contribute to the pathophysiology of SAD (21, 22). CCL18 is predominantly secreted by tissue-resident alveolar macrophages and increased serum concentrations are likely proportionate to numbers of the innate immune cells present within the airway (23). Serving as a pro-inflammatory chemokine, our finding that CCL18 is significantly elevated in the COPD groups is suggestive of increased airway inflammation.

In COPD, CT is the method used for imaging and diagnosing the key morphological changes, including SAD and emphysema (20). Quantitative approaches help us to overcome subjectivity in sub-classifying the extent and severity of emphysema and gas trapping related more to SAD than emphysema (24, 25, 26). Vasilescu et al. validated the capability of non-invasive PRM CT biomarkers and showed their ability to identify SAD and emphysema morphology (14). Pompe et al. added to the value of using PRM and observed that PRMfSAD and PRMEmph biomarkers were associated with clinical parameters of lung function test, allowing them to identify the presence and severity of COPD (27). Consistent with our other

results, we demonstrated that PRMfSAD and PRMEmph were less impaired in disCOPD than conCOPD patients. This fits with disCOPD being a pre-COPD state, where radiological evidence of disease is present. Disease progression models in COPD suggest that most patients progress from SAD and emphysema to large airway changes over time, rather than the opposite (28).

This study was limited by lower than anticipated recruitment, which is related to the overlap with the Covid-19 pandemic UK peaks. Numbers in this study were lower than in other studies of discordant COPD (29, 30). Similarly, this limited our ability to appropriately age- and sex-match our cohorts; for lung function and oscillometry measures, we report percentage predicted values, which account for these confounders. We chose not to stratify by severity of COPD partly for this reason, but also because the distribution of lung function demonstrated that most patients had mild disease (the target population for recruitment to the study). We also only report cross-sectional data, whereas longitudinal studies of spirometry have been able to give evidence of temporal changes (8). Our ethics committee did not allow CT scanning of healthy controls, although disCOPD patients were still able to be compared with conCOPD.

Despite these absences, a major strength of this study is the breadth of investigations used to investigate our stated aim. Rather than relying on one single measure, we have used symptoms, physiology, radiology, and serum biochemistry to holistically assess the clinical relevance of disCOPD, and overall have found a cohesive message: disCOPD patients appear to have similar features to conCOPD, including when compared with healthy controls. This is applicable to the interpretation of the GOLD 2024 report, which advocates the use of a 0.7 FEV1/FVC threshold for COPD diagnosis but expresses reservations about over-diagnosis in the elderly, and to UK national guidance, which does not mention the LLN (31, 32). Our data support the use of the 0.7 threshold in clinical practice, and suggests that, rather than representing over-diagnosis, disCOPD spirometry with symptoms represents disease status.

Use of the 0.7 threshold is likely to make spirometry interpretation easier for the non-specialist and identify COPD at an earlier stage. Identifying the disease at an early stage is likely to have multiple benefits for patients: aside from starting pharmacology earlier, they will be able to access COPD and exacerbation management plans, smoking cessation guidance, physiotherapy where indicated, and annual review policies. These approaches all aim to slow progression of the disease, and by accessing them earlier, a greater proportion of lung function may be preserved. Future research could assess asymptomatic patients with this spirometry pattern over time, to see what proportion develop symptoms and FEV1/FVC <LLN. Assessing relation of this potential 'pre-COPD' state to risk factors for fixed airflow obstruction, such as family history of airways disease might also be of interest.

Conclusion

Our data concur with GOLD and suggests that symptomatic patients with FEV1/FVC ratio <0.7, but above the lower limit of normal, are not over-diagnosed with COPD, but instead represent a clinically significant subset of the disease. When paired with a high clinical suspicion of COPD, such spirometry should trigger holistic investigation, including further lung function and radiology.

References

1. Digital N. Quality and Outcomes Frameworks. 2020-2021.
2. Higham A, Quinn AM, Cançado JED, Singh D. The pathology of small airways disease in COPD: historical aspects and future directions. Respiratory Research. 2019;20(1):49.
3. Cosio M, Ghezzo H, Hogg JC, Corbin R, Loveland M, Dosman J, et al. The Relations between Structural Changes in Small Airways and Pulmonary-Function Tests. New England Journal of Medicine. 1978;298(23):1277-81.
4. Alvar A, Bartolome RC, Gerard JC, David H, Antonio A, Peter B, et al. Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary. European Respiratory Journal. 2023;61(4):2300239.
5. Mehrdad A, Siyang Z, Igor B, Barr RG, Eugene RB, Russell PB, et al. Radiographic lung volumes predict progression to COPD in smokers with preserved spirometry in SPIROMICS. European Respiratory Journal. 2019;54(4):1802214.
6. Arina M, Alice MT. Identifying the at risk smokers: who goes on to get COPD? European Respiratory Journal. 2019;54(4):1901613.
7. Thomas EG, M; Straus, SE; Bell, KJ; Glasziou, P. Rate of normal lung function decline in ageing adults: a systematic review of prospective cohort studies. BMJ Open. 2019;9(6):499.

8.   Guerra S, Sherrill DL, Venker C, Ceccato CM, Halonen M, Martinez FD. Morbidity and mortality associated with the restrictive spirometric pattern: a longitudinal study. Thorax. 2010;65(6):499-504.

9.   Lu J, Ge H, Qi L, Zhang S, Yang Y, Huang X, et al. Subtyping preserved ratio impaired spirometry (PRISm) by using quantitative HRCT imaging characteristics. Respiratory Research. 2022;23(1):309.

10.   Chukowry PS, Spittle DA, Turner AM. Small airways disease, biomarkers and COPD: Where are we? Int J Chron Obstruct Pulmon Dis. 2021;16:351-65.

11.   The Birmingham 1000 Healthy Elders Group

12.   Arnardottir NY, Koster A, Van Domelen DR, Brychta RJ, Caserotti P, Eiriksdottir G, et al. Objective measurements of daily physical activity patterns and sedentary behaviour in older adults: Age, Gene/Environment Susceptibility-Reykjavik Study. Age Ageing. 2013;42(2):222-9.

13.   Troiano RP, Berrigan D, Dodd KW, Mâsse LC, Tilert T, McDowell M. Physical activity in the United States measured by accelerometer. Med Sci Sports Exerc. 2008;40(1):181-8.

14.   Vasilescu DM, Martinez FJ, Marchetti N, Galbán CJ, Hatt C, Meldrum CA, et al. Noninvasive Imaging Biomarker Identifies Small Airway Damage in Severe Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine. 2019;200(5):575-81.

15.   Nathan SD, Flaherty KR, Glassberg MK, Raghu G, Swigris J, Alvarez R, et al. A Randomized, Double-Blind, Placebo-Controlled Study of Pulsed, Inhaled Nitric Oxide in Subjects at Risk of Pulmonary Hypertension Associated With Pulmonary Fibrosis. Chest. 2020;158(2):637-45.

16.   Han MK, Ye W, Wang D, White E, Arjomandi M, Barjaktarevic IZ, et al. Bronchodilators in Tobacco-Exposed Persons with Symptoms and Preserved Lung Function. New England Journal of Medicine. 2022;387(13):1173-84.

17.   Guerra S, Halonen M, Vasquez MM, Spangenberg A, Stern DA, Morgan WJ, et al. Relation between circulating CC16 concentrations, lung function, and development of chronic obstructive pulmonary disease across the lifespan: a prospective study. Lancet Respir Med. 2015;3(8):613-20.

18.   James Michael W, Margaret MP, Robert AO, Russell PB, Mark TD, Surya PB, et al. Elevated circulating MMP-9 is associated with increased exacerbation risk in COPD: results from SPIROMICS and COPDGene. European Respiratory Journal. 2018;52(suppl 62):PA3857.

19.   Brajer B, Batura-Gabryel H, Nowicka A, Kuznar-Kaminska B, Szczepanik A. Concentration of matrix metalloproteinase-9 in serum of patients with chronic obstructive pulmonary disease and a degree of airway obstruction and disease progression. J Physiol Pharmacol. 2008;59 Suppl 6:145-52.

20.   Kristoffer O, Nicholas W, Viktoriya K, Michael B, Stephen H, Lindsay W, et al. Relationship between pulmonary matrix metalloproteinases and quantitative CT markers of small airways disease and emphysema in COPD. Thorax. 2016;71(2):126.

21.   Lazar MH, Christensen PJ, Du M, Yu B, Subbotina NM, Hanson KE, et al. Plasminogen Activator Inhibitor–1 Impairs Alveolar Epithelial Repair by Binding to Vitronectin. Am J Respir Cell Mol Biol. 2004;31(6):672-8.

22.   Wang H, Yang T, Li D, Wu Y, Zhang X, Pang C, et al. Elevated circulating PAI-1 levels are related to lung function decline, systemic inflammation, and small airway obstruction in chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease. 2016;11(null):2369-76.

23.   Rong B, Fu T, Rong C, Liu W, Li K, Liu H. Association between serum CCL-18 and IL-23 concentrations and disease progression of chronic obstructive pulmonary disease. Scientific Reports. 2020;10(1):17756.

24.   Galbán CJ, Han MK, Boes JL, Chughtai KA, Meyer CR, Johnson TD, et al. Computed tomography–based biomarker provides unique signature for diagnosis of COPD phenotypes and disease progression. Nature Medicine. 2012;18(11):1711-5.

25.   Lidén M, Hjelmgren O, Vikgren J, Thunberg P. Multi-Reader–Multi-Split Annotation of Emphysema in Computed Tomography. Journal of Digital Imaging. 2020;33(5):1185-93.

26.   Smith BM, Austin JHM, Newell JD, D'Souza BM, Rozenshtein A, Hoffman EA, et al. Pulmonary Emphysema Subtypes on Computed Tomography: The MESA COPD Study. The American Journal of Medicine. 2014;127(1):94.e7-.e23.

27.   Pompe E, Galbán CJ, Ross BD, Koenderman L, ten Hacken NHT, Postma DS, et al. Parametric response mapping on chest computed tomography associates with clinical and functional parameters in chronic obstructive pulmonary disease. Respiratory Medicine. 2017;123:48-55.

28.   Young AL, Bragman FJS, Rangelov B, Han MK, Galbán CJ, Lynch DA, et al. Disease Progression Modeling in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine. 2019;201(3):294-302.

29.   Guder G, Brenner S, Angermann CE, Ertl G, Held M, Sachs AP, et al. "GOLD or lower limit of normal definition? A comparison with expert-based diagnosis of chronic obstructive pulmonary disease in a prospective cohort-study". Respir Res. 2012;13(1):13.

30.   van Dijk W, Tan W, Li P, Guo B, Li S, Benedetti A, et al. Clinical relevance of fixed ratio vs lower limit of normal of FEV1/FVC in COPD: patient-reported outcomes from the CanCOLD cohort. Ann Fam Med. 2015;13(1):41-8.

31.   National Institute for Health and Care Excellence: Guidelines. Chronic obstructive pulmonary disease in over 16s: diagnosis and management. London: National Institute for Health and Care Excellence (NICE) Copyright © NICE 2018.; 2019.

32.   Agusti A, Celli B, Criner GJ, Halpin D, Lopez Varela MV, de Oca MM, et al. GLOBAL STRATEGY FOR PREVENTION, DIAGNOSIS AND MANAGEMENT OF COPD: 2024 Report. Global Initiative for Chronic Obstructive Lung Disease; 2024.

Figure 1: Lung volumes from CT imaging

Box-and-whisker plots comparing the total pulmonary volume measured in litres (L) in discordant COPD (disCOPD) and concordant COPD (conCOPD) groups using parametric response mapping (PRM) as a quantitative computer tomography (CT) predictive measure. Mann-Whitney tests were performed to compare two individual groups. A, total pulmonary volumes at the peak of inspiration; B, total lung volume throughout the entire lung at the peak of expiration.

Figure 2: Gas trapping measured by PRM

Box-and-whisker plots comparing the proportional normal pulmonary function (PRM Norm) in discordant COPD (disCOPD) and concordant COPD (conCOPD) groups using parametric response mapping (PRM) as a quantitative computer tomography (CT) predictive measure. PRM data shown as the percentage of the total lung volume Mann-Whitney tests were performed to compare two individual groups.

Figure 3: Box-and-whisker plots comparing the proportional emphysematous (PRMEmph) change and functional small airways disease (SAD) (PRMfSAD) in discordant COPD (disCOPD) and concordant COPD (conCOPD) groups using parametric response mapping (PRM) as a quantitative computer tomography (CT) predictive measure. Mann-Whitney tests were performed to compare two individual groups. A, proportional emphysematous extent change; B, proportional functional small airways disease.

Symptoms of COPD in the absence of airflow obstruction are more indicative of pre-COPD than overdiagnosis – supplementary material

Description of commercially-available kits used for biomarker quantification

CC-16 was measured using Human Uteroglobin Quantikine ELISA kit (R&D Systems, Minneapolis, MN, USA); RAGE using Human RAGE Quantikine ELISA kit (R&D Systems); SP-D using Luminex® Discovery Assay (LXSAHM-01) (Bio-Techne Limited, Minneapolis, MN, USA); MMP-8, MMP9 and MMP-12 using Luminex® Human MMP Premixed Kit (Bio-Techne Limited); PAI-1 using Luminex® Human Obesity Premixed Kit (Bio-Techne Limited); CCL18 using Invitrogen PARC/CCL18 Human ELISA kit (Fisher Scientific, Waltham, MA, USA). For biomarkers measured using ELISA, GraphPad Prism 8 version 9.0 (Boston, MS, USA) was used to create standard curves and interpolation of unknown concentrations.

Details of CT scan methodology

Spiral CT images were taken at 120 kVP, mAs automatically modulated, 1mm slice thickness, with a reconstructed Br64f kernel. Scan quality was assessed before quantitative analysis was carried out. Imbio CT Lung Density Analysis™ Software (Imbio, LLC, Minneapolis, MN, v4.1.0) was used for image registration of the paired CT scans and for segmentation of the pulmonary tissue. A voxel-wise map was created with parametric response mapping (PRM), which enabled spatial alignment of inspiratory and expiratory images, thus facilitating regional quantification. Segmentation of lungs and lobes was carried out, with airways excluded from the analysis. During PRM analysis, specific thresholds were set to categorise the voxels. Areas of interest containing features of total pulmonary volume, normal pulmonary function (PRM Norm), functional SAD (PRMfSAD) and emphysema (PRMEmph) were

measured. The classification criteria described by Vasilescu et al. were applied as follows: PRM Norm: inspiration, ≥ -950 Hounsfield Units (HU), expiration, ≥ -856 HU, green; PRMfSAD: inspiration, ≥ -950 HU, expiration, < -856 HU, yellow; PRMEmph: inspiration, < -950 HU, expiration, < -856 HU, red (14). Total, right, left and segmented inspiratory and expiratory pulmonary volumes were recorded.

Step 1: Every patients with COPD participated in dedicated respiratory training sessions.

Step 2: COPD patients underwent CT scans, with careful adjustments made to the CT acquisition parameters.

Step 3: Performed both inspiratory and expiratory scans to evaluate and assess for the presence of emphysema and small airways disease.

Inspiration scan   Expiration scan

Step 4: Image processing used Imbio CT Lung Density Analysis^{TM}
An advanced automated image post-processing algorithm designed to precisely identify and delineate the location and extent of tissue damage. This cutting-edge solution offers both comprehensive visualisation and precise quantification of regions displaying abnormal CT tissue density.

Step 5: Inputs: using functional assessment workflow and parametric response mapping (PRM) processes. During the functional mapping process, the segments are applied to both images (label the lobes of the lungs), followed by registering the inspiration image to the expiration image (enabling a pairwise mapping analysis of the lung images). The images undergo thresholding, followed by the classification of each pair of voxels.

The overlay assigns distinct colour codes to individual lung tissue voxels, facilitating the categorization of tissue into one of three classification groups:

1. Normal Pulmonary Function (PRM Norm):
· Inspiration: ≥ -950 HU,
· Expiration: ≥ -856 HU,
· Colour Code: Green

2. Functional Small Airways Disease (PRMfSAD):
· Inspiration: ≥ -950 HU,
· Expiration: < -856 HU,
· Colour Code: Yellow

3. Emphysematous Change (PRMEmph):
· Inspiration: < -950 HU,
· Expiration: < -856 HU,
· Colour Code: Red

Step 6: Outputs: the functional assessment workflow produces two primary outcomes: a functional assessment map and report. This workflow involves the labeling and computation of lung density statistics for the following specific regions within the lung lobes: upper right, middle right, lower right, upper left, and lower left. Total pulmonary volume, right and left lung pulmonary volumes and segmented inspiration and expiratory pulmonary volumes were recorded.

Segmentation algorithm

Registration algorithm

Thresholding and classification algorithm

Supplementary Figure 1: A schematic diagram of the Parametric response mapping (PRM) technique process using Imbio computer tomography (CT) Lung Density Analysis^{TM}. This approach categorises lung attenuation maps by analysing each voxel independently. It achieves this by aligning inspiratory and expiratory images to determine a comprehensive measure of small airway disease and emphysema, including their local distribution and extent. The analysis of the PRM technique consists of the following steps: respiratory training sessions, CT scan acquisition, acquisition of inspiratory and expiratory scanning, image processing, and classification using Imbio software. Image processing started with lung segmentation, followed by registering the inspiration image to the expiration image, thresholding, and finally the classification of each pair of voxels. Then, voxels from attenuation maps can be put into different groups. This lets the clinicians measure and diagnose lung diseases like normal lung (PRM Norm, green), small airway disease (PRMfSAD, yellow), and emphysematous (PRMEmph, red). COPD-Chronic obstructive pulmonary disease.

Supplementary Table 1: Parametric response mapping (PRM) computer tomography (CT)-based quantitative measure for total pulmonary volume measured in litres (L), proportional normal pulmonary function (PRM Norm), proportional emphysematous (PRMEmph) change and functional small airways disease (SAD) (PRMfSAD) in discordant COPD (disCOPD) and concordant COPD (conCOPD) groups using parametric response mapping (PRM) as a quantitative computer tomography (CT) predictive measure. Descriptive statistical analysis. L-left lung; R-right lung; SAD- small airways disease; Emph- emphysematous change; VOL-volume; Insp-inspiration; Exp-expiration; IQR- Interquartile range; COPD- Chronic obstructive pulmonary disease.

CT PRM biomarker	Unit of measurement	disCOPD		conCOPD		Difference	p value
		Median	IQR	Median	IQR		
Total_Normal_Lung	Percentage (%)	49	10	43	10	6	0.2407
Total_Normal_L_Lung	Percentage (%)	51	9	43	12	8	0.1908
Normal_Upper_L_Lung	Percentage (%)	48	9	43	7	5	0.5886
Normal_Middle_L_Lung	Percentage (%)	50	6	40	12	10	0.1134
Normal_Lower_L_Lung	Percentage (%)	55	11	50	15	5	0.1580
Total_Normal_R_Lung	Percentage (%)	50	14	41	9	9	0.3296
Normal_Upper_R_Lung	Percentage (%)	47	16	40	8	7	0.2979
Normal_Middle_R_Lung	Percentage (%)	51	10	41	12	10	0.1796
Normal_Lower_R_Lung	Percentage (%)	52	9	45	14	7	0.3653
SAD_Total_Lung	Percentage (%)	26	5	29	4	-3	0.1896
SAD_Total_L_Lung	Percentage (%)	23	5	27	4	-4	0.2401
SAD_Upper_L_Lung	Percentage (%)	26	7	30	5	-4	0.4190
SAD_Middle_L_Lung	Percentage (%)	23	8	27	6	-4	0.1385
SAD_Lower_L_Lung	Percentage (%)	19	8	23	7	-4	0.4209
SAD_Total_R_Lung	Percentage (%)	25	4	29	6	-4	0.1483
SAD_Upper_R_Lung	Percentage (%)	26	6	31	7	-5	0.1577
SAD_Middle_R_Lung	Percentage (%)	26	5	29	5	-3	0.1048
SAD_Lower_R_Lung	Percentage (%)	21	7	28	7	-7	0.0724
Emph_Total_Lung	Percentage (%)	12	7	14	6	-2	0.2538
Emph_Total_L_Lung	Percentage (%)	12	5	13	7	-1	0.2021
Emph_Upper_L_Lung	Percentage (%)	12	5	14	3	-2	0.6328
Emph_Middle_L_Lung	Percentage (%)	10	4	15	8	-5	0.1042
Emph_Lower_L_Lung	Percentage (%)	8	5	10	8	-2	0.1472
Emph_Total_R_Lung	Percentage (%)	11	7	15	5	-4	0.3825
Emph_Upper_R_Lung	Percentage (%)	12	8	16	5	-4	0.2825
Emph_Middle_R_Lung	Percentage (%)	11	6	15	6	-4	0.2383
Emph_Lower_R_Lung	Percentage (%)	10	3	13	7	-3	0.4196
Total_Lung_VOL_Insp	Litters (L)	5.2	1.5	5.9	1.3	-0.7	0.1390
L_Lung_VOL_Insp	Litters (L)	2.4	0.6	2.8	0.7	-0.4	0.1121
R_Lung_VOL_Insp	Litters (L)	2.7	0.9	3.1	0.7	-0.4	0.2013
Total_Lung_VOL_Exp	Litters (L)	3.5	1.0	4.1	1.2	-0.6	0.1391
L_Lung_VOL_Exp	Litters (L)	1.7	0.6	1.9	0.4	-0.2	0.2140
R_Lung_VOL_Exp	Litters (L)	1.8	0.5	2.1	0.8	-0.3	0.1210